{"@context":"http://iiif.io/api/presentation/2/context.json","@type":"sc:Manifest","@id":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/9da4266d-3ebb-4ea7-8d3f-0f397eb698a8/manifest","label":"Raul Caballero Montes - UCD 2021 Liver Cancer Immunotherapies","metadata":[{"label":"School Affiliation","value":["School of Natural & Social Sciences"]},{"label":"Metadata Creator","value":"car"},{"label":"Source","value":"Raul Caballero Montes - UCD 2021 Liver Cancer Immunotherapies"},{"label":"Format","value":["Document (PDF)"]},{"label":"Rights","value":["open access"]},{"label":"Language","value":["English"]},{"label":"Subject","value":["Hepatocellular Carcinoma","Liver Disease","Chronic Disease","Cancer","HCC","Immunotherapies","Onco-Immunology","Immune Checkpoints Inhibitors"]},{"label":"Publisher","value":"Texas Wesleyan University"},{"label":"Type","value":["text"]},{"label":"Description","value":"Statistics posits that hepatocellular carcinoma is responsible for approximately 80% of lung cancer-related deaths. The increase in death cases has resulted in extensive research concerning disease control, emphasizing liver cancer immunotherapies. In the literature review, emphasis is placed on the various immunotherapies, emphasizing inhibitors such as PD-1/PD-L1 and CTL4/ B7-1/B7-2. The adoption of inhibitors in the treatment of HCC has presented positive results, hence a possible breakthrough for the HCC. As inscribed in the review, the European Society of Medical Oncology study presents immune checkpoint inhibitors (ICIs) with a high percentage of HCC treatment success. The study on PD-1 expresses itself in the form of T cells, B cells, and NK cells. The ligands expressed in PD-1 include PD-L1. The study on the CTLA-4/PD-1 co-inhibitors has resulted in the anti-tumor immune response, hence a possible breakthrough in the HCC treatment. The literature review seeks to present diverse information in relation to the HCC treatment with inhibitors as the significant point of concentration. The review covers the use of PD-1/PD-L1 and CTL-4 as the major immunotherapies for the HCC treatment. However, other remedies such as chemotherapy, chemoradiography, and radiography in liver cancer treatment are not considered in the literature review."},{"label":"Date","value":"D:00 M:00 Y:2021"},{"label":"Title","value":"Liver Cancer and Immunotherapies: Are We Able to Engineer the Body to Stop Hepatocellular Carcinoma (HCC)?"},{"label":"Faculty Sponsor","value":"Smeller, Carl"},{"label":"Creator","value":["Montes, Raul Caballero"]},{"label":"Format Genre","value":["University College Day"]},{"label":"Department Affiliation","value":["Biology"]},{"label":"Date Added","value":"6/3/2021"},{"label":"Repository","value":["Academic Archive"]}],"description":"Liver Cancer and Immunotherapies: Are We Able to Engineer the Body to Stop Hepatocellular Carcinoma (HCC)?","sequences":[{"@type":"sc:Sequence","canvases":[{"@id":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/9da4266d-3ebb-4ea7-8d3f-0f397eb698a8/canvas/_1","@type":"sc:Canvas","label":"Raul Caballero Montes - UCD 2021 Liver Cancer Immunotherapies-1","height":1125,"width":2001,"images":[{"@type":"oa:Annotation","motivation":"sc:painting","resource":{"@id":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/4d64ac76-51ec-4bbc-9e43-78f3828b0aa6/full/full/0/default.jpg","@type":"dctypes:Image","format":"image/jpeg","service":{"@context":"http://iiif.io/api/image/2/context.json","@id":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/4d64ac76-51ec-4bbc-9e43-78f3828b0aa6","profile":"http://iiif.io/api/image/2/level2.json","tiles":[{"width":512,"scaleFactors":[1,2,4]}]},"height":1125,"width":2001},"on":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/9da4266d-3ebb-4ea7-8d3f-0f397eb698a8/canvas/_1","metadata":[]}],"thumbnail":{"@id":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/4d64ac76-51ec-4bbc-9e43-78f3828b0aa6/full/500,500/0/default.jpg","@type":"dctypes:Image","height":500,"width":500}}]}],"thumbnail":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/4d64ac76-51ec-4bbc-9e43-78f3828b0aa6/full/300,300/0/default.jpg","logo":"https://iiif.quartexcollections.com/texas-wesleyan/iiif/logo"}